Arizona is currently home to 1684 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of the Impact of Empty Versus Full Bladder in Patients with Prostate Cancer, RELIEF Trial
NCT06037863
Recruiting
This clinical trial evaluates the effects of an empty bladder versus (vs.) a full bladder prior to undergoing a computed tomography (CT) simulation for radiation therapy in patients with prostate cancer. Radiation therapy is a commonly used treatment for men diagnosed with prostate cancer. Prior to initiation of a course of radiotherapy, all patients with prostate cancer undergo a CT simulation that allows for computer-based optimization of radiation dose delivery to the target tissue (i.e., pro... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Prostate Carcinoma
Register for Updates
Enhancing Language Function in Aphasia
NCT05443633
Recruiting
Aphasia is an acquired impairment of language, that commonly results from damage to language areas in the brain (typically the left side of the brain). This impairment is seen in many aspects of language, including understanding, speaking, reading and writing. It is estimated that about 2 million individuals are currently living with aphasia in the United States. Further, about 200,000 Americans acquire aphasia every year (National Aphasia Association, 2020). Aphasia poses significant impact on... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
12/04/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Aphasia, Acquired, Language Disorders, Primary Progressive Aphasia, Stroke, Cerebrovascular
Register for Updates
AngelMed Guardian® System PMA Post Approval Study
NCT05412927
Recruiting
500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care. Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/04/2024
Locations: Southwest Cardiovascular Associates, Mesa, Arizona
Conditions: Acute Coronary Syndrome
Register for Updates
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444
Recruiting
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona
Conditions: Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Register for Updates
Rehydration Efficiency During Ad-libitum Fluid Intake
NCT06414291
Recruiting
It is well established that rehydration with a carbohydrate-electrolyte solution is more effective in comparison to plain water. This is primarily based on the sodium-glucose co transporter, based on which the world health organization has based its oral rehydration solution recommendations. Also, rehydration with a solution that includes sodium and glucose plasma osmolality should not drop as much as it happens during rehydration with water. As a result, we should have higher fluid intake due t... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/03/2024
Locations: Interdisciplinary Science and Technology Building 8, Phoenix, Arizona
Conditions: Dehydration
Register for Updates
4D-150 in Patients With Diabetic Macular Edema
NCT05930561
Recruiting
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Retinal Research Institute LLC, Phoenix, Arizona
Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Register for Updates
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT05710848
Recruiting
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Arizona Urology Specialists, Tucson, Arizona
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
NCT05699603
Recruiting
This phase IIA study evaluates the effects of calcipotriene plus 5- fluorouracil immunotherapy for skin cancer prevention in organ transplant recipients. Solid organ transplant recipients are at high risk of developing skin cancer. Actinic keratosis (AK), is a premalignant skin lesion that can progress to squamous cell skin cancer. In this study, solid organ transplant recipients with multiple AKs are treated with topical calcipotriene and 5-FU to evaluate how effective this therapy is against A... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona
Conditions: Actinic Keratosis
Register for Updates
Role of Gut Microbiome in Cancer Therapy
NCT05112614
Recruiting
This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatment is delivered, and increase its effectiveness and success.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/03/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia
NCT05111288
Recruiting
This study is being done to observe the effects of treatment from a device called the Bioboosti which utilizes pulsed electromagnetic waves on its ability to improve blood flow to the heart tissue in individuals with coronary artery disease (CAD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Coronary Artery Disease, Myocardial Infarction
Register for Updates
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
NCT06173505
Recruiting
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Palo Verde Cancer Specialists, Glendale, Arizona
Conditions: Nonsquamous Non-small Cell Lung Cancer
Register for Updates
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
NCT05152524
Recruiting
The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/27/2024
Locations: Honor Health, Phoenix, Arizona
Conditions: Ischemic Stroke, Neovascularization
Register for Updates